SDS
SDS Number: 00010002001 Revision Date: 1/12/2016
health effects. Direct eye contact may cause irritation.
EFFECT OF OVEREXPOSURE - INGESTION: Under normal use conditions, this product is not expected to cause adverse health
effects. Single dose oral toxicity is very low. Amounts ingested incidental to industrial handling are not likely to cause injury; however,
ingestion of large amounts may cause injury.
CARCINOGENICITY: No Information
EFFECT OF OVEREXPOSURE - CHRONIC HAZARDS: Repeated or prolonged exposure may cause irritation of eyes and skin.
The International Agency for Research on Cancer (IARC) has determined that crystalline silica in the form of quartz or cristobalite that
is inhaled from occupational sources is carcinogenic to humans (Group 1- carcinogenic to humans). Refer to IARC Monograph 68,
Silica, Some Silicates and Organic Fibres (published in June 1997) in conjunction with the use of these materials. The National
Toxicology Program (NTP) classifies respirable crystalline silica as "known to be a human carcinogen". Refer to the 9th Report on
Carcinogens (2000). The American Conference of Governmental Industrial Hygienists (ACGIH) classifies crystalline silica, quartz, as
a suspected human carcinogen (Group A2). Breathing dust containing respirable crystalline silica may not cause noticeable injury or
illness even though permanent lung damage may be occurring. Inhalation of dust may have the following serious chronic health
effects: Excessive inhalation of respirable dust can cause pneumoconiosis, a respiratory disease, which can result in delayed,
progressive, disabling and sometimes fatal lung injury. Symptoms include cough, shortness of breath, wheezing, non-specific chest
illness and reduced pulmonary function. Smoking exacerbates this disease. Individuals with pneumoconiosis are predisposed to
develop tuberculosis. There is some evidence that breathing respirable crystalline silica or the disease silicosis is associated with an
increased incidence of significant disease endpoints such as scleroderma (an immune system disorder manifested by fibrosis of the
lungs, skin and other internal organs) and kidney disease.
PRIMARY ROUTE(S) OF ENTRY: Inhalation, Skin Contact
Acute Toxicity Values
The acute effects of this product have not been tested. Data on individual components are tabulated below
CAS-No. Chemical Name Oral LD50 Dermal LD50 Vapor LC50
1317-65-3 Limestone 6450 mg/kg Rat >2000 mg/kg >20 mg/L
27138-31-4 Dipropylene glycol dibenzoate 5368 mg/kg Rat >2000 mg/kg Rabbit >200 mg/L Rat
64741-88-4 Petroleum distillates >5000 mg/kg Rat >2000 mg/kg Rabbit 2.18 mg/L Rat
120-55-8 Diethylene glycol dibenzoate 2830 mg/kg Rat 2000 mg/kg Rabbit > 200 mg/L Rat
13463-67-7 Titanium dioxide >10000 mg/kg Rat >5000 mg/kg Rabbit >20 mg/L
14808-60-7 Quartz 500 mg/kg Rat >2000 mg/kg >20 mg/L
1333-86-4 Carbon black >8000 mg/kg Rat >3000 mg/kg Rabbit N.I.
N.I. = No Information
12. Ecological Information
ECOLOGICAL INFORMATION: Ecological injuries are not known or expected under normal use.
13. Disposal Information
DISPOSAL INFORMATION: This product does not meet the definition of a hazardous waste according to U.S. EPA Hazardous
Waste Management Regulation, 40 CFR Section 261. Dispose as hazardous waste according to all local, state, federal and provincial
regulations. State and Local regulations/restrictions are complex and may differ from Federal regulations. Responsibility for proper
waste disposal is with the owner of the waste.
14. Transport Information
SPECIAL TRANSPORT PRECAUTIONS: No Information
DOT UN/NA Number: N.A.
DOT Proper Shipping Name: Not Regulated.
DOT Technical Name: N.A.
DOT Hazard Class: N.A.
Hazard SubClass: N.A.
Packing Group: N.A.
Page 4 / 6